PAGE-B Risk Score

ShareIn the original validation study, which included Caucasian adults with chronic hepatitis B who had received entecavir or tenofovir for at least 12 months, patients with PAGE-B scores ≤9, 10-17, and ≥18 had 5-year cumulative HCC incidence rates of 0%, 3-4%, and 16-17%. The authors noted that PAGE-B scores ≤9 likely indicate minimal 5-year HCC risk, while PAGE-B scores ≥10 and particularly ≥18 indicate increased HCC risk requiring ongoing surveillance.

Note: The 2023 AASLD HCC guidelines recognize PAGE-B as one of the more validated tools for HCC risk stratification but stop short of endorsing it—or any specific score—for routine clinical use due to concerns about predictive accuracy. It does however include a PAGE-B score ≥10 as an indication for HCC screening among people with chronic hepatitis B.

---